More than 5% of the world’s population are healthy carriers of a gene for sickle-cell disease.
In some regions, over 25% of people are carriers.
Every year more than 5 million children are born with sickle cell trait, and over 400,000 are born with sickle cell disease.
Newborn screening is not widespread in low-resource regions and sickle cell disease has up to 80% childhood mortality, without proper treatment.
Newborn screening followed up with available, inexpensive treatment significantly reduces sickle cell disease mortality.
HemoTypeSC™ is a rapid test kit for the determination of hemoglobin type in whole blood. HemoTypeSC™ provides point-of-care determination of hemoglobin phenotypes Hb AA (normal), Hb SS and Hb SC (sickle cell disease), Hb CC (hemoglobin C disease), and Hb AS and Hb AC (carrier or trait).
In January, 2018, HemoTypeSC™ was utilized at Holy Family Hospital in Techiman, Ghana to screen over 400 newborns, infants, children, and adult parents for hemoglobins A, S, and C. This two minute video tells the story.
Healthcare professionals using HemoTypeSC™ describe the positive outcomes for patients in clinics and hospitals around the world.